Heterodimerization and cross-desensitization between the mu-opioid receptor and the chemokine CCR5 receptor.

Cross-desensitization between micro-opioid receptor agonists and CC chemokines was shown to occur in immune cells and in the central nervous system. However, these cells do not permit examination of potential mechanisms at cellular levels due to low levels and mixed populations of receptors. In this study, we investigated possible interactions and biochemical mechanisms of cross-desensitization between the mu-opioid and chemokine CCR5 receptors coexpressed in Chinese hamster ovary (CHO) cells. Hemagglutinin (HA)-tagged micro-opioid receptor coimmunoprecipitated with FLAG (Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys)-tagged chemokine receptor CCR5 in cells expressing the two receptors, but not in a mixture of cells transfected with one of the two receptors, indicating that the two receptors form heterodimers. Treatment with the mu-opioid receptor agonist DAMGO ([D-Ala(2), N-Me-Phe(4), Gly(5)-ol]-enkephalin), the chemokine RANTES (Regulated on Activation, Normal T cell-Expressed and -Secreted) (CCL5), or both, did not affect the level of coimmunoprecipitation. DAMGO and RANTES (CCL5) induced chemotaxis in CHO cells coexpressing both receptors, and preincubation with either DAMGO or RANTES (CCL5) profoundly inhibited chemotaxis caused by the other. DAMGO pretreatment enhanced phosphorylation of the chemokine CCR5 receptor and reduced RANTES (CCL5)-promoted [35S]GTP gamma S binding. Conversely, RANTES (CCL5) preincubation slightly increased phosphorylation of the mu-opioid receptor and significantly reduced DAMGO-induced [35S]GTP gamma S binding. These results indicate that activation of either receptor affected G protein coupling of the other, likely due to enhanced phosphorylation of the receptor. Heterodimerization between the two receptors may contribute to the observed cross-desensitization.

[1]  A. Maghazachi.  Intracellular signalling pathways induced by chemokines in natural killer cells. , 1999, Cellular signalling.

[2]  L. Devi,et al.  Heterodimerization of G-protein-coupled receptors: pharmacology, signaling and trafficking. , 2001, Trends in pharmacological sciences.

[3]  H. Loh,et al.  Molecular mechanisms and regulation of opioid receptor signaling. , 2000, Annual review of pharmacology and toxicology.

[4]  H Weinstein,et al.  Functional role of the spatial proximity of Asp114(2.50) in TMH 2 and Asn332(7.49) in TMH 7 of the μ opioid receptor , 1999, FEBS letters.

[5]  J. K. de Riel,et al.  Characterization of Irreversible Binding of -Funaltrexamine to the Cloned Rat Opioid Receptor (*) , 1995, The Journal of Biological Chemistry.

[6]  G A McPherson,et al.  A practical computer-based approach to the analysis of radioligand binding experiments. , 1983, Computer programs in biomedicine.

[7]  S. Friedman,et al.  HIV infection and intravenous drug use: critical issues in transmission dynamics, infection outcomes, and prevention. , 1988, Reviews of infectious diseases.

[8]  J. Brugge,et al.  Integrins and signal transduction pathways: the road taken. , 1995, Science.

[9]  Ping Wang,et al.  Chemokine receptor CCR5 functionally couples to inhibitory G proteins and undergoes desensitization , 1998, Journal of cellular biochemistry.

[10]  H. Loh,et al.  The Absence of a Direct Correlation between the Loss of [d-Ala2,MePhe4,Gly5-ol]Enkephalin Inhibition of Adenylyl Cyclase Activity and Agonist-induced μ-Opioid Receptor Phosphorylation* , 1999, The Journal of Biological Chemistry.

[11]  Michel Bouvier,et al.  Dimerization: an emerging concept for G protein-coupled receptor ontogeny and function. , 2002, Annual review of pharmacology and toxicology.

[12]  M. Oppermann,et al.  Differential Effects of CC Chemokines on CC Chemokine Receptor 5 (CCR5) Phosphorylation and Identification of Phosphorylation Sites on the CCR5 Carboxyl Terminus* , 1999, The Journal of Biological Chemistry.

[13]  R. Snyderman,et al.  Chemoattractant Receptors Activate Distinct Pathways for Chemotaxis and Secretion , 1999, The Journal of Biological Chemistry.

[14]  W. Müller-Esterl,et al.  Receptor phosphorylation does not mediate cross talk between muscarinic M(3) and bradykinin B(2) receptors. , 1999, The American journal of physiology.

[15]  B. Ashby,et al.  Agonist-induced desensitization and down-regulation of the human kappa opioid receptor expressed in Chinese hamster ovary cells. , 1998, The Journal of pharmacology and experimental therapeutics.

[16]  T. Molitor,et al.  The opioid–cytokine connection , 1998, Journal of Neuroimmunology.

[17]  J. Traynor,et al.  Modulation by mu-opioid agonists of guanosine-5'-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells. , 1995, Molecular pharmacology.

[18]  B. Cullen,et al.  Molecular mechanism of desensitization of the chemokine receptor CCR‐5: receptor signaling and internalization are dissociable from its role as an HIV‐1 co‐receptor , 1997, The EMBO journal.

[19]  Henry R. Bourne,et al.  Receptors induce chemotaxis by releasing the βγ subunit of Gi, not by activating Gq or Gs , 1997 .

[20]  A. Ben-Baruch,et al.  Opiate Inhibition of Chemokine‐Induced Chemotaxis , 1998, Annals of the New York Academy of Sciences.

[21]  D. Taub,et al.  Opiates transdeactivate chemokine receptors: delta and mu opiate receptor-mediated heterologous desensitization. , 1998 .

[22]  B. Premack,et al.  Activation of dual T cell signaling pathways by the chemokine RANTES. , 1995, Science.

[23]  G. Milligan,et al.  Oligomerisation of G-protein-coupled receptors. , 2001, Journal of cell science.

[24]  Brigitte L. Kieffer,et al.  Recent advances in molecular recognition and signal transduction of active peptides: Receptors for opioid peptides , 1995, Cellular and Molecular Neurobiology.

[25]  Cairns Js,et al.  Chemokines and HIV-1 second receptors: The therapeutic connection , 1998 .

[26]  R. DesJarlais,et al.  ASP147 in the third transmembrane helix of the rat mu opioid receptor forms ion-pairing with morphine and naltrexone. , 1999, Life sciences.

[27]  I. Charo,et al.  Differential Regulation of G-protein-mediated Signaling by Chemokine Receptors* , 1996, The Journal of Biological Chemistry.

[28]  T. Eisenstein,et al.  Opioids, opioid receptors, and the immune response. , 2001, Drug and alcohol dependence.

[29]  G Vassart,et al.  Molecular cloning and functional expression of a new human CC-chemokine receptor gene. , 1996, Biochemistry.

[30]  H. Weinstein,et al.  Constitutive activation of the mu opioid receptor by mutation of D3.49(164), but not D3.32(147): D3.49(164) is critical for stabilization of the inactive form of the receptor and for its expression. , 2001, Biochemistry.

[31]  D. Linzer,et al.  Printed in U.S.A. Copyright © 1997 by The Endocrine Society Proliferin Induces Endothelial Cell Chemotaxis through a G Protein-Coupled, Mitogen-Activated Protein Kinase- Dependent Pathway* , 1997 .

[32]  C. Martínez-A,et al.  Chemokine signaling and functional responses: the role of receptor dimerization and TK pathway activation. , 2001, Annual review of immunology.

[33]  Chongguang Chen,et al.  Selective inactivation of CCR5 and decreased infectivity of R5 HIV‐1 strains mediated by opioid‐induced heterologous desensitization , 2003, Journal of leukocyte biology.

[34]  Ji Ming Wang,et al.  Inhibition of chemokine-induced chemotaxis of monkey leukocytes by mu-opioid receptor agonists. , 1999, In vivo.

[35]  M. Caron,et al.  Mutational Analysis of Gβγ and Phospholipid Interaction with G Protein-coupled Receptor Kinase 2* , 2000, The Journal of Biological Chemistry.

[36]  A. Mantovani,et al.  Rapid induction of arachidonic acid release by monocyte chemotactic protein-1 and related chemokines. Role of Ca2+ influx, synergism with platelet-activating factor and significance for chemotaxis. , 1994, The Journal of biological chemistry.

[37]  R. DesJarlais,et al.  Determination of the Amino Acid Residue Involved in [3H]β-Funaltrexamine Covalent Binding in the Cloned Rat μ Opioid Receptor* , 1996, The Journal of Biological Chemistry.

[38]  I. Charo,et al.  Chemotaxis in a lymphocyte cell line transfected with C-C chemokine receptor 2B: Evidence that directed migration is mediated by βγ dimers released by activation of Gαi-coupled receptors , 1997 .

[39]  R. Bonavia,et al.  Characterization of chemokines and their receptors in the central nervous system: physiopathological implications , 2002, Journal of neurochemistry.

[40]  Lei Fang,et al.  Molecular biology and pharmacology of cloned opioid receptors 1 , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[41]  S. Holmberg,et al.  The estimated prevalence and incidence of HIV in 96 large US metropolitan areas. , 1996, American journal of public health.

[42]  G. Bokoch.  Chemoattractant signaling and leukocyte activation. , 1995, Blood.

[43]  F. F. Weight,et al.  Differential Opiate Receptor Phosphorylation and Desensitization Induced by Agonists and Phorbol Esters (*) , 1996, The Journal of Biological Chemistry.

[44]  R. Doi,et al.  Interactions of opioid and chemokine receptors: oligomerization of mu, kappa, and delta with CCR5 on immune cells. , 2002, Experimental cell research.

[45]  M. Caron,et al.  Phosphorylation of the mammalian beta-adrenergic receptor by cyclic AMP-dependent protein kinase. Regulation of the rate of receptor phosphorylation and dephosphorylation by agonist occupancy and effects on coupling of the receptor to the stimulatory guanine nucleotide regulatory protein. , 1985, The Journal of biological chemistry.

[46]  J. Wang,et al.  Opioids suppress chemokine-mediated migration of monkey neutrophils and monocytes - an instant response. , 2000, Immunopharmacology.

[47]  D. Dimitrov,et al.  Down-regulation of the chemokine receptor CCR5 by activation of chemotactic formyl peptide receptor in human monocytes. , 2000, Blood.

[48]  T. Rogers,et al.  Ca2+-independent Protein Kinase Cs Mediate Heterologous Desensitization of Leukocyte Chemokine Receptors by Opioid Receptors* , 2003, The Journal of Biological Chemistry.

[49]  M. Adler,et al.  Heterologous desensitization of opioid receptors by chemokines inhibits chemotaxis and enhances the perception of pain , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[50]  Lei Yu,et al.  Molecular cloning and functional expression of a mu opioid receptor from rat brain , 1994, Regulatory Peptides.

[51]  T. Rogers,et al.  Bidirectional Heterologous Desensitization of Opioid and Chemokine Receptors , 2000, Annals of the New York Academy of Sciences.

[52]  A. Proudfoot.  Chemokine receptors: multifaceted therapeutic targets , 2002, Nature Reviews Immunology.

[53]  D. Mangoura,et al.  μ‐Opioids activate tyrosine kinase focal adhesion kinase and regulate cortical cytoskeleton proteins cortactin and vinculin in chick embryonic neurons , 1997, Journal of neuroscience research.

[54]  M. Caron,et al.  Role of phosphorylation in desensitization of the β-adrenoceptor , 1990 .

[55]  R. Snyderman,et al.  Chemoattractant Receptor Cross-desensitization* , 1999, The Journal of Biological Chemistry.

[56]  C. Hague,et al.  Heterodimerization of G Protein-Coupled Receptors: Specificity and Functional Significance , 2005, Pharmacological Reviews.